EBMT-Case Studies on Innovative Treatment Approaches for CMV in HCT

Activity Overview

Join us for cutting edge insights on clinically challenging cases of cytomegalovirus (CMV) infection in hematopoietic cell transplant (HCT) patients. Test your knowledge about CMV and learn about emerging therapies for minimizing bone marrow toxicity and improving outcomes.
Location: IFEMA Feria de Madrid | Madrid, Spain

LIVE ACTIVITY

Target Audience

This educational activity is designed for practicing clinicians, including hematology and infectious disease specialist clinicians in the United States and Europe, who manage cytomegalovirus (CMV) infection and disease in hematopoietic cell transplant (HCT) patients.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

Select anti-cytomegalovirus (CMV) therapy in hematopoietic cell transplant (HCT) patients using evidence-based therapeutic approaches and knowledge of emerging therapies in clinical trials
Manage CMV treatments in HCT patients based on viral load, side effect profile, and consideration of antiviral resistance
Differentiate between CMV recurrence, resistance, or late recurrence and implement appropriate therapies
Describe the burden of CMV infection in HCT patients, including the impact of CMV seropositivity and indirect effects

Activity Faculty

Jan Styczynski, MD (Moderator)

Chairman, EBMT Infectious Diseases Working Party
Department of Pediatric Hematology and Oncology
Collegium Medicum
Nicolaus Copernicus University
Bydgoszcz, Poland

Per Ljungman, MD, PhD

Professor, Hematology
Karolinska University Hospital
Stockholm, Sweden

Johan Maertens, MD, PhD

Associate Professor, Hematology
University Hospitals Leuven
Leuven, Belgium